Maraviroc:in vitro assessment of drug–drug interaction potential
Open accessThe DOI matches its Crossref record.
Abstract
WHAT IS ALREADY KNOWN ABOUT THE SUBJECT • Maraviroc is known to undergo oxidative metabolism in vivo and is a substrate for cytochrome P450 (CYP). • Simcyp™ has recently become more widely used for the prediction of CYP‐mediated drug–drug interactions (DDIs) using in vitro metabolism data. WHAT THIS STUDY ADDS • Maraviroc has been identified as a CYP3A4 substrate and the kinetic constants characterized. • The predicted DDIs associated with maraviroc as a CYP3A4 substrate using Simcyp™ have been compared against the clinical data. • This study demonstrates the value of a reliable Simcyp™ model for prediction of DDIs. AIMS: To characterize the cytochrome P450 enzyme(s) responsible for the N‐dealkylation of maraviroc in vitro, and predict the extent of clinical drug–drug interactions (DDIs). METHODS: Human liver and recombinant CYP microsomes were used to identify the CYP enzyme responsible for maraviroc N‐dealkylation. Studies comprised enzyme kinetics and evaluation of the effects of specific CYP inhibitors.In vitro data were then used as inputs for simulation of DDIs with ketoconazole, ritonavir, saquinavir and atazanvir, using the Simcyp™ population‐based absorption, distribution, metabolism and elimination (ADME) simulator. Study designs for simulations mirrored those actually used in the clinic. RESULTS: Maraviroc was metabolized to its N‐dealkylated product via a single CYP enzyme characterized by a K mof 21 µM and Vmax of 0.45 pmol pmol−1 min−1 in human liver microsomes and was inhibited by ketoconazole (CYP3A4 inhibitor). In a panel of recombinant CYP enzymes, CYP3A4 was identified as the major CYP responsible for maraviroc metabolism. Using recombinant CYP3A4, N‐dealkylation was characterized by a K mof 13 µM and a Vmax of 3 pmol pmol−1 CYP min−1. Simulations therefore focused on the effect of CYP3A4 inhibitors on maraviroc pharmacokinetics. The simulated median AUC ratios were in good agreement with observed clinical changes (within twofold in all cases), although, in general, there was a trend for overprediction in the magnitude of the DDI. CONCLUSION: Maraviroc is a substrate for CYP3A4, and exposure will therefore be modulated by CYP3A4 inhibitors. Simcyp™ has successfully simulated the extent of clinical interactions with CYP3A4 inhibitors, further validating this software as a good predictor of CYP‐based DDIs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science
Rowland, M., Peck, C., & Tucker, G. (2011) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100540 · Cited by 662
The Simcyp ® Population-based ADME Simulator
Jamei, M., Marciniak, S., Feng, K., Barnett, A., Tucker, G., & Rostami-Hodjegan, A. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250802691074 · Cited by 533
Sager, J. E., Yu, J., Ragueneau-Majlessi, I., & Isoherranen, N. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.065920 · Cited by 518
Shebley, M., Sandhu, P., Emami Riedmaier, A., Jamei, M., Narayanan, R., Patel, A., Peters, S. A., Reddy, V. P., Zheng, M., de Zwart, L., et al. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1013 · Cited by 395
Metadata
- Authors
- Hyland, R., Dickins, M., Collins, C., Jones, H., & Jones, B.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2008-09-11
- Volume
- 66
- Issue
- 4
- Pages
- 498-507
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W2063228933
- Cited by
- 90
- References
- 0
- FWCI
- 7.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Maraviroc:in vitro assessment of drug–drug interaction potential. https://app.cochat.ai/papers/10.1111/j.1365-2125.2008.03198.x
- The paper
- Hyland, R., Dickins, M., Collins, C., Jones, H., & Jones, B. (2008). Maraviroc:in vitro assessment of drug–drug interaction potential. British Journal of Clinical Pharmacology. https://doi.org/10.1111/j.1365-2125.2008.03198.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.